Profile data is unavailable for this security.
About the company
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The Company has three product platforms. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune, developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that has completed a trial in recessive dystrophic epidermolysis bullosa.
- Revenue in USD (TTM)50.00k
- Net income in USD-49.89m
- Incorporated2015
- Employees22.00
- LocationINmune Bio Inc225 Ne Mizner Blvd, Suite 640BOCA RATON 33432United StatesUSA
- Phone+1 (858) 964-3720
- Websitehttps://www.inmunebio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Axe Compute Inc | 728.20k | -84.01m | 33.98m | 23.00 | -- | -- | -- | 46.66 | -120.02 | -120.66 | 1.29 | -100.94 | 0.1369 | 1.34 | 2.97 | 31,660.87 | -1,579.84 | -85.09 | -- | -113.42 | 50.24 | 61.31 | -11,536.93 | -1,267.27 | 0.0134 | -0.1392 | -- | -- | -0.2384 | 2.84 | 9.63 | -- | -18.60 | -- |
| Cypherpunk Technologies Inc | 0.00 | -50.81m | 34.48m | 52.00 | -- | 9.36 | -- | -- | -1.23 | -1.23 | 0.00 | 0.065 | 0.00 | -- | -- | 0.00 | -132.94 | -79.03 | -196.76 | -93.29 | -- | -- | -- | -9,055.53 | -- | -- | 0.00 | -- | -- | -- | 16.74 | -- | -- | -- |
| Xilio Therapeutics Inc | 31.80m | -58.49m | 35.11m | 64.00 | -- | -- | -- | 1.10 | -0.6571 | -0.6571 | 0.3348 | -0.1562 | 0.3053 | -- | -- | 496,937.50 | -56.14 | -67.88 | -102.68 | -81.71 | -- | -- | -183.90 | -5,578.28 | -- | -2.84 | -- | -- | -- | -- | 23.77 | -- | -45.00 | -- |
| Protext Mobility Inc | 750.00 | -2.21m | 35.16m | 4.00 | -- | -- | -- | 46,886.52 | -0.4692 | -0.4692 | 0.00001 | -0.0102 | 0.0405 | -- | -- | -- | -9,400.97 | -1,587.94 | -- | -- | 86.67 | -530.19 | -232,392.00 | -17,498.83 | 0.0002 | -1.36 | -- | -- | -93.98 | -63.09 | 27.35 | -- | -- | -- |
| Jasper Therapeutics Inc | 0.00 | -91.02m | 35.54m | 64.00 | -- | 3.07 | -- | -- | -5.90 | -5.90 | 0.00 | 0.4135 | 0.00 | -- | -- | 0.00 | -116.04 | -75.11 | -147.54 | -86.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -10.55 | -- | -- | -- |
| Veru Inc | 0.00 | -15.68m | 35.95m | 20.00 | -- | 1.79 | -- | -- | -1.07 | -1.55 | 0.00 | 1.25 | 0.00 | -- | -- | 0.00 | -34.75 | -47.51 | -44.42 | -59.79 | -- | -- | -- | -188.81 | -- | -- | 0.00 | -- | -- | -- | 55.53 | -- | -60.02 | -- |
| Cell Source Inc | 0.00 | -6.57m | 36.03m | -- | -- | -- | -- | -- | -0.1613 | -0.1613 | 0.00 | -0.4379 | 0.00 | -- | -- | -- | -2,039.39 | -1,758.85 | -- | -- | -- | -- | -- | -- | -- | -3.74 | -- | -- | -- | -- | -3.55 | -- | -- | -- |
| Galecto Inc | 0.00 | -15.84m | 36.10m | 5.00 | -- | 4.51 | -- | -- | -12.01 | -12.01 | 0.00 | 6.03 | 0.00 | -- | -- | 0.00 | -92.89 | -47.05 | -109.09 | -50.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 44.10 | -- | -- | -- |
| PDS Biotechnology Corp | 0.00 | -34.88m | 36.15m | 24.00 | -- | 3.48 | -- | -- | -0.8194 | -0.8194 | 0.00 | 0.1982 | 0.00 | -- | -- | 0.00 | -80.05 | -57.93 | -125.74 | -68.38 | -- | -- | -- | -- | -- | -8.43 | 0.6552 | -- | -- | -- | 12.42 | -- | -- | -- |
| Actinium Pharmaceuticals Inc | 90.00k | -34.60m | 36.19m | 37.00 | -- | 2.63 | -- | 402.08 | -1.11 | -1.11 | 0.0029 | 0.4419 | 0.0013 | -- | -- | 2,432.43 | -50.05 | -43.20 | -55.95 | -47.84 | -- | -- | -38,443.33 | -7,408.74 | -- | -- | 0.0009 | -- | -100.00 | -- | 21.66 | -- | -29.66 | -- |
| INmune Bio Inc | 50.00k | -49.89m | 37.75m | 22.00 | -- | 1.49 | -- | 755.02 | -2.14 | -2.14 | 0.0021 | 0.9546 | 0.0012 | -- | 0.0258 | 2,272.73 | -115.83 | -45.54 | -153.59 | -52.16 | -- | -- | -99,774.00 | -19,298.45 | -- | -942.22 | 0.00 | -- | -90.97 | -- | -40.24 | -- | -- | -- |
| Generation Bio Inc | 15.27m | -62.63m | 38.68m | 115.00 | -- | 0.7647 | -- | 2.53 | -9.35 | -9.35 | 2.28 | 7.51 | 0.0824 | -- | 11.73 | 132,782.60 | -33.79 | -35.85 | -39.21 | -38.42 | -- | -- | -410.13 | -2,304.98 | -- | -- | 0.00 | -- | 236.92 | -- | -3.99 | -- | -34.55 | -- |
| Aligos Therapeutics Inc | 2.65m | -86.46m | 39.94m | 70.00 | -- | 0.556 | -- | 15.09 | -12.70 | -12.70 | 0.2964 | 11.67 | 0.0267 | -- | -- | 37,800.00 | -87.25 | -60.83 | -111.39 | -72.31 | -- | -- | -3,267.65 | -1,462.14 | -- | -- | 0.002 | -- | -74.60 | -- | -49.65 | -- | -45.83 | -- |
| Lisata Therapeutics Inc | 1.07m | -18.24m | 40.58m | 26.00 | -- | 2.32 | -- | 37.92 | -2.13 | -2.13 | 0.1246 | 1.98 | 0.0357 | -- | -- | 41,153.85 | -60.85 | -44.77 | -71.25 | -49.07 | -- | -- | -1,704.86 | -13,065.70 | -- | -- | 0.00 | -- | -- | -- | 4.10 | -- | -- | -- |
| CEL-SCI Corp | 0.00 | -25.41m | 41.20m | 43.00 | -- | 2.46 | -- | -- | -7.81 | -7.81 | 0.00 | 1.99 | 0.00 | -- | -- | -- | -92.16 | -72.20 | -111.94 | -80.91 | -- | -- | -- | -- | 2.20 | -38.20 | 0.3328 | -- | -- | -- | 7.86 | -- | -57.33 | -- |
| ABVC Biopharma Inc | 797.92k | -4.12m | 41.28m | 16.00 | -- | 3.21 | -- | 51.74 | -0.2223 | -0.2223 | 0.0464 | 0.4985 | 0.0448 | -- | 0.408 | 49,870.00 | -24.89 | -105.17 | -42.73 | -217.00 | 0.2469 | 75.19 | -555.90 | -2,124.21 | 0.6241 | -13.71 | 0.0662 | -- | 234.31 | -6.20 | 37.05 | -- | -- | -- |
Data as of Feb 06 2026. Currency figures normalised to INmune Bio Inc's reporting currency: US Dollar USD
13.45%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Sep 2025 | 1.10m | 4.15% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 830.54k | 3.12% |
| Geode Capital Management LLCas of 30 Sep 2025 | 469.44k | 1.77% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 283.83k | 1.07% |
| Raymond James Financial Services Advisors, Inc.as of 30 Sep 2025 | 253.50k | 0.95% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2025 | 189.12k | 0.71% |
| Susquehanna Financial Group LLLPas of 30 Sep 2025 | 156.95k | 0.59% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 122.77k | 0.46% |
| Westside Investment Management LLCas of 31 Dec 2025 | 108.95k | 0.41% |
| UBS Financial Services, Inc.as of 31 Dec 2025 | 57.10k | 0.22% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
